Dopamantine

Dopamantine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name SCH-15507; also known as N-adamantanoyl dopamine) is an antiparkinsonian drug of the adamantane group that developed for treatment of Parkinson's disease but was never marketed.^{[1][2][3][4][5][6]} It was developed and studied in the 1970s and was said to have reached early clinical trials.^[1][6][4]

Other namesSCH-15507; Sch 15507; N-Adamantanoyl dopamine; NSC-172619

CAS Number

• 39907-68-1

PubChem CID

• 38361

ChemSpider

• 35160

Quick facts Clinical data, Other names ...

Dopamantine

Clinical data
Other names	SCH-15507; Sch 15507; N-Adamantanoyl dopamine; NSC-172619
Identifiers
IUPAC name N-[2-(3,4-dihydroxyphenyl)ethyl]adamantane-1-carboxamide
CAS Number	39907-68-1
PubChem CID	38361
ChemSpider	35160
UNII	7EZN745FXZ
KEGG	D03890
ChEMBL	ChEMBL2106204
CompTox Dashboard (EPA)	DTXSID70192961
ECHA InfoCard	100.049.707
Chemical and physical data
Formula	C19H25NO3
Molar mass	315.413 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1C2CC3CC1CC(C2)(C3)C(=O)NCCC4=CC(=C(C=C4)O)O
InChI InChI=1S/C19H25NO3/c21-16-2-1-12(8-17(16)22)3-4-20-18(23)19-9-13-5-14(10-19)7-15(6-13)11-19/h1-2,8,13-15,21-22H,3-7,9-11H2,(H,20,23) Key:ZWKFENYDXISLGK-UHFFFAOYSA-N

Close

Dopamantine combines elements of the chemical structures of clinically used adamantane antiparkinsonian agents like amantadine and dopamine or levodopa (L-DOPA) into a single molecule.^[3][4] It is said to have been designed to help dopamine cross the blood–brain barrier via the lipophilic adamantane moiety.^[5] The drug is said to share pharmacological effects with amantadine.^[4] Another related compound is carmantadine, which is also an adamantane antiparkinsonian agent that was never marketed.^[4][6]